


NEWSRELEASE

DELMEDICAINVESTMENTS November 29th 2006



Delmedica offers the private equity investor access to unique biotechnology opportunities that have the hallmarks of commercially successful ventures.



INTERASMA Appoints Dunev Inventors

www.interasma.org

Interasma

INTERASMA (the International Association of Asthmology) has recently announced the appointment of Professor Todor Popov to the role of President.

INTERASMA's global operations are devoted to encouraging asthma education and prevention programs throughout the world. Their tireless efforts in promoting the International Guidelines of Asthma are aimed at improving quality of life for some 300 million people afflicted with the world's fastest growing chronic disease.

A Professor at the University of Sofia Clinical Centre for Allergology, Dr. Popov is a globally recognised Allergologist, sitting on the Boards of numerous bodies active in the fields of Allergological Science and Medicine. Dr. Popov has also written numerous preeminent papers and journals on the subject of asthma intervention.

INTERASMA has further announced the appointment of Dr DuBuske as Secretary General.

Dr Popov and Dr DuBuske are esteemed members of the Fortune Apex Development Scientific Advisory Board, having made invaluable contributions towards the development of the Dunev Thermometer.

We take this opportunity to thank Dr Popov and Dr DuBuske for their ongoing commitment to the prevention of asthma and wish them every success in their new roles with the world's foremost Asthma Organisation.

International Association
of Asthmology



Dunev Inventor To Address International Symposium

On the 9th November 2006, Dr Alexander Popov addressed the INTERASMA Symposium in Philadelphia, a specialised forum reviewing Global Trends in Asthma Management.

Dr Popov presented a detailed paper outlining the objectives and methodology for assessing bronchial inflammation as a means towards preventing asthma attacks.

INTERASMA has further announced the

appointment of Dr DuBuske as Secretary General.

The presentation extolled the use of exhaled breath temperature devices in improving asthma management as supported by the remarkable clinical outcomes of the Dunev Thermometer.

Keynotes from Dr Popov's address to the INTERASMA Symposium can be viewed in detail by visiting www.delmedicainvestments.com

Strategic Joint Venture Signed



Fortune Apex Development Ltd ('Fortune Apex') has recently authorised a Joint Venture Company with Strategic Pharmaceutical Advisors, Inc ('SrxA').

The Joint Venture Company 'Strategic Pharmaceuticals Company LLC' ('SPC')* have appointed specialist advisors with management to be provided by SrxA.

SPC has been granted an exclusive Global license for a defined period to handle sales and marketing for the commercialisation of 'MUCOAD™' technology. Marketing will be conducted under the brand 'Strategic Biosciences' further information for which

can be accessed through the Fortune Apex web site at www.fortuneapex.com, following the hyperlink under 'relevant resources' or via www.rxbiosci.com.

Non Disclosure and Confidentiality Agreements have already been signed with a number of pharmaceutical companies with presentations ongoing to develop relationships and foster licensing agreements. The Fortune Apex Scientific Advisory Board will assist to provide the scientific documentation as required to support the commercialisation objectives.

The directors of Fortune Apex consider the Strategic Partnership a key opportunity to develop all licensing and commercialisation of the MUCOAD™ technology by enlisting the considerable resources and industry expertise available to SrxA.

The Joint Venture represents a significant step for both parties aimed at increasing exposure and expediting market penetration for MUCOAD™.

*Registered in Delaware, USA. Offices at 1000 Potomac Street, N.W., Suite 151, Washington, DC. 20007

www.delmedicainvestments.com

DELMEDICA

DELMEDICAINVESTMENTS NEWS RELEASE